Eidos Therapeutics, Inc. (EIDX)
(Delayed Data from NSDQ)
$25.98 USD
+1.19 (4.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $25.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.98 USD
+1.19 (4.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $25.98 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for November 3rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares
by Zacks Equity Research
Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.
Company News for Oct 6, 2020
by Zacks Equity Research
Companies in the news are: TSLA, MYOK, EIDX, GAN
New Strong Sell Stocks for September 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Eidos Therapeutics (EIDX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Eidos Therapeutics (EIDX) Stock Might be a Great Pick
by Zacks Equity Research
Eidos Therapeutics (EIDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Eidos Therapeutics, Inc. (EIDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alexion (ALXN) Collaborates With Stealth BioTherapeutics
by Zacks Equity Research
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
by Zacks Equity Research
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
by Zacks Equity Research
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.